Multi-source·Jul 27, 2026·2 sources analyzed
Federal judge rejected FDA limits on mifepristone access
A federal judge said FDA restrictions on mifepristone were arbitrary and capricious, keeping a live court and agency fight over medication-abortion rules before regulators, litigants and Congress. (sources: law.justia.com, www.theguardian.com)
Image: Modern Action subject: Rules for medication abortion care
Modern Action Briefing
The ruling challenges existing FDA regulations on mifepristone, which may affect medication-abortion access in the United States.
- A federal judge ruled that the FDA's restrictions on mifepristone were arbitrary and capricious.
- The ruling could affect the availability of medication-abortion services.
- The decision may lead to changes in FDA regulations regarding mifepristone.
Why it matters
The ruling may influence access to medication-abortion options in the U.S.
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on Rules for medication abortion care
See the current decision, choose your position, and send a message through the issue page.
Take action on Rules for medication abortion care